Dr. Santomasso on Managing CNS Toxicity from CAR T-Cell Therapy for B-Cell Lymphoma

Video

Bianca D. Santomasso, MD, PhD, discusses how she prevents central nervous system toxicity due to CAR T-cell therapy for aggressive B-cell lymphoma in her own practice.

Bianca D. Santomasso, MD, PhD, assistant attending neurologist, Memorial Sloan Kettering Cancer Center, discusses how she prevents central nervous system toxicity due to CAR T-cell therapy for aggressive B-cell lymphoma in her own practice.

Santomasso and her colleagues perform the Immune Effector Cell Encephalopathy (ICE) screening at least once daily on patients who have received CAR T-cell therapy. The perfect score on ICE is 10 and when a patient's score drops to 9, they start to be monitored more closely.

Severe cases of neurotoxicity can progress beyond language and disorientation to seizures and even falling into a coma, explains Santomasso. When patients have severe toxicity, they are given corticosteroids. Santomasso is unsure how the corticosteroids reverse the toxicity, but she believes they prevent the most severe progression as the toxicity runs its course. Some patients spontaneously recover without steroids, but corticosteroids are usually given to be safe. In Santomasso’s experience, giving corticosteroids has not changed the efficacy of treatment, though it is a subject being actively researched.

Recent Videos
David Barrett, JD, the chief executive officer of ASGCT
Georg Schett, MD, vice president research and chair of internal medicine at the University of Erlangen – Nuremberg
David Barrett, JD, the chief executive officer of ASGCT
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Caroline Diorio, MD, FRCPC, FAAP, an attending physician at the Cancer Center at Children's Hospital of Philadelphia
R. Nolan Townsend; Sandi See Tai, MD; Kim G. Johnson, MD
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Paul Melmeyer, MPP, the executive vice president of public policy & advocacy at MDA
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Related Content
© 2024 MJH Life Sciences

All rights reserved.